The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care.
Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
https://pubmed.ncbi.nlm.nih.gov/41348481/Actively Recruiting
Led by University of Colorado, Denver · Updated on 2025-05-06
126
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effect of a glucagon-like peptide 1 receptor agonist GLP-1RA, a medication approved for weight management that also improves glucose and insulin response, on slowing kidney growth in adults with autosomal dominant polycystic kidney disease ADPKD who are overweight or obese. This phase II, randomized, placebo-controlled, double-blind clinical trial aims to determine if one year of treatment can slow kidney growth, as well as assess changes in abdominal fat and kidney metabolism using advanced imaging techniques. The study also collects blood and urine samples to explore biological changes linked to treatment benefits while monitoring safety and tolerability. Participants will receive either tirzepatide, a GLP-1RA drug, or a placebo. The dosing starts at 2.5 mg once weekly and escalates to 5 mg once weekly after 4 weeks, maintaining the target dose for 10 months. Dose adjustments are allowed to manage side effects, with a minimum tolerated dose of 2.5 mg per week required to continue. Both study groups follow the same dose-escalation regimen, and all dose changes are recorded. During the 12-month study, participants undergo assessments at baseline, 6 months, and 12 months including magnetic resonance imaging to measure kidney volume and abdominal fat, blood tests for inflammation and metabolism markers, and urine tests. Researchers monitor kidney growth as the primary outcome and track secondary measures such as body weight, insulin resistance, and kidney oxygen consumption. Safety and tolerability are carefully followed throughout the study period, with total participation lasting one year.
CONDITIONS
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
K
Kristen Nowak, PhD, MPH
D
Diana George
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Colorado, Denver
Lead Sponsor
Washington University School of Medicine
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Tirzepatide (weekly, titrated) | Placebo (weekly, titrated) |
|---|---|---|
| What is it? | A glucagon-like peptide-1 (GLP-1) receptor agonist (tirzepatide) given by weekly subcutaneous injection, titrated to 5 mg. | A matching placebo given as weekly subcutaneous injection, titrated to an identical schedule as in the investigational arm. |
| Role in trial | Investigational arm receiving active medication under study for its effect on kidney and metabolic outcomes in ADPKD with obesity. | Control group receiving placebo to isolate the effects of tirzepatide in otherwise similar participants. |
| Primary use in this context | Evaluated for its potential to reduce increase in height-adjusted total kidney volume and impact metabolic and inflammatory markers in ADPKD with obesity. | Serves as a comparator to assess the effects of tirzepatide, with no expected active impact on kidney or metabolic endpoints. |
| How it is given | Once weekly subcutaneous injection, titrated to 5 mg. | Once weekly subcutaneous injection, matching the titration schedule of the investigational arm. |
| Clinical evidence status | Efficacy and safety in ADPKD with obesity are under investigation in this and other emerging clinical studies. Published reviews identify an urgent need for new therapies beyond current options, but conclusive evidence for GLP-1 receptor agonists in ADPKD is not yet established. | Placebo does not have efficacy in treating ADPKD or obesity; serves to isolate effects of investigational drug in this context. |
| Important limitations | The use of tirzepatide in ADPKD is not yet standard practice; long-term effects on kidney volume, function, and metabolic parameters have not been established. Evidence remains preliminary and derived from ongoing trials and emerging research rather than large, definitive studies. | Placebo neither benefits nor harms ADPKD or obesity, but does not provide clinically meaningful intervention for disease progression or associated metabolic complications. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive weekly subcutaneous injections of tirzepatide or placebo with a dose-escalation regimen over 12 months to evaluate effects on kidney growth and metabolic health.
Regular visits with dose adjustments as needed during the first 2 months, followed by monthly visits for the remaining 10 months
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
https://pubmed.ncbi.nlm.nih.gov/41348481/Christopher Y Chen, Mohamad Hadla, Ibrahim Khambati...
https://pubmed.ncbi.nlm.nih.gov/41385299/University of Colorado, Denver
Lead Sponsor
Washington University School of Medicine
Collaborating Sponsor